Corvus Pharmaceuticals CRVS Equity Method Income
Equity Method Income at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's equity method income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's equity method income?
- Corvus Pharmaceuticals (CRVS) reported equity method income of -$599K in Q1 2026.
- How has Corvus Pharmaceuticals's equity method income changed year-over-year?
- Corvus Pharmaceuticals's equity method income decreased by 11.1% year-over-year, from -$539K to -$599K.
- What is the long-term trend for Corvus Pharmaceuticals's equity method income?
- Over 3 years (2022 to 2025), Corvus Pharmaceuticals's equity method income has grown at a -41.9% compound annual growth rate (CAGR), from -$10.01M to -$1.96M.
- What does equity method income mean?
- The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.